Kato M, Shinohara H, Goto S, Takagi K, Soma G
Department of Urology, Saitama Medical School, Japan.
Anticancer Res. 1998 Sep-Oct;18(5D):3941-9.
Exogenous/endogenous TNF (EET) therapy has a strong effect which causes inflammation in the body. Together with the antitumor effect of a single administration, the complementary effect of immunotherapy based on specific immunostimulation of tumor cells is also expected. We studied the characteristics of EET therapy in cases of advanced cancer.
The patients were 75 cases with advanced cancer including 48 cases of colon cancer, 10 cases of urological cancer, and 9 cases of gynecological cancer. One course of therapy was composed of the intravenous administration of either IFN-gamma or TNF-SAM2 followed 3 hours later by OK-432. At least 2 courses were repeated during a 2 weeks period.
As response cases, partial response (PR) was observed in 7 of the 42 cases of colon cancer (17%) which had an evaluable lesion. Objective responses of lung metastases were found in the patients with multiple organ metastases of cervical cancer, ovarian cancer and uterine rhabdomyosarcoma. The group of colorectal cancer patients with liver metastases which underwent more than 5 courses of the therapy showed a longer survival period compared to the control group. One of the side effects, transitory hypotension, was observed in 46% of the cases.
In spite of restricted objective responses to date with EET therapy alone, anticancer effects observed in various kinds of tumors and activation of a cytokine network by which Th1 cells might be specifically activated suggest that a new biotherapy based on EET therapy may have potential.
外源性/内源性肿瘤坏死因子（EET）疗法具有强大的效应，可引发体内炎症。除单次给药的抗肿瘤作用外，基于对肿瘤细胞进行特异性免疫刺激的免疫疗法的协同作用也备受期待。我们研究了晚期癌症患者中EET疗法的特点。
患者共75例晚期癌症患者，其中结肠癌48例，泌尿系统癌症10例，妇科癌症9例。一个疗程的治疗包括静脉注射γ干扰素或肿瘤坏死因子-SAM2，3小时后再注射OK-432。在2周内至少重复2个疗程。
作为有效病例，在42例有可评估病灶的结肠癌患者中，7例（17%）出现部分缓解（PR）。在宫颈癌、卵巢癌和子宫横纹肌肉瘤多器官转移的患者中发现了肺转移灶的客观缓解。接受超过5个疗程治疗的伴有肝转移的结直肠癌患者组与对照组相比生存期更长。46%的病例出现了一种副作用，即短暂性低血压。
尽管目前单独使用EET疗法的客观缓解有限，但在各种肿瘤中观察到的抗癌作用以及可能特异性激活Th1细胞的细胞因子网络的激活表明，基于EET疗法的新生物疗法可能具有潜力。
